Search clinical trials for: IMS001

Total 213 results

ImStem Biotechnology
Rho, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States
Immatics Biotechnologies GmbH
Bristol-Myers Squibb

Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
Maruho Co., Ltd.

Completed

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

Acne Vulgaris

United States
Maruho Co., Ltd.

Completed

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Atopic Dermatitis

Netherlands
Peking Union Medical College Hospital
Beijing Immupeutics Medicine Technology Limited

Recruiting

Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Maruho Co., Ltd.

Completed

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

Papulopustular Rosacea

United States
Vesper Biotechnologies ApS

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants (SORT-IN-1)

Dementia, Frontotemporal

Netherlands
Biotheus Inc.

Not yet recruiting

A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours

Advanced Solid Tumours
Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Canada, Netherlands, New Zealand, Australia, Sweden
Samyang Biopharmaceuticals Corporation

Not yet recruiting

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

Crow's Feet Lines
Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Netherlands, Sweden
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Fudan University

Active, not recruiting

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Triple Negative Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Suzhou Immunofoco Biotechnology Co., Ltd
Changhai Hospital

Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Gastric Cancer | Pancreatic Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Ovarian Carcinoma

China
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
ImmuneWorks

Completed

Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; Southwest Hospital, China; Daping Hospital...

Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Huashan Hospital
Peking University People's Hospital; Beijing Immupeutics Medicine Technology...

Not yet recruiting

Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Ever Supreme Bio Technology Co., Ltd.

Recruiting

Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke

Acute Stroke

Taiwan
Maruho Co., Ltd.
Leiden University Medical Center

Completed

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Condylomata Acuminata (External)

Netherlands
Capella Bioscience Ltd
Centessa Pharmaceuticals plc

Terminated

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Chronic Inflammatory Disease

United Kingdom
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Sun Yat-sen University

Active, not recruiting

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Immunis, Inc.

Recruiting

Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Muscle Atrophy

United States
Maruho Co., Ltd.

Completed

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

Netherlands
Maruho Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
ImevaX

Completed

Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers (IMX-02)

Helicobacter Pylori Infected Subjects | Helicobacter Pylori Naive Subjects

Germany
Omeros Corporation

Completed

Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones

Urinary Calculi | Urinary Stones | Urinary Tract Stones

United States
Immatics Biotechnologies GmbH

Completed

IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (IMA901-202)

Renal Cell Carcinoma

Spain, Germany, Bulgaria, United Kingdom, Austria, Hungary, Poland, Romania, Slovakia, Switzerland
Xu jianmin

Unknown

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Medexus Pharma, Inc.

Completed

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Hemophilia B

United States, France, United Kingdom, India, Israel, Italy, Poland
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Omeros Corporation

Completed

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

Urinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract Stones

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Department of Defense; Walter Reed Army Institute... and other collaborators

Completed

Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults

Malaria | Plasmodium Vivax

United States
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit / Hyperactivity Disorder

Japan
Northern Jiangsu Province People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Radiotherapy | Immunotherapy

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Suzhou Immunofoco Biotechnology Co., Ltd

Recruiting

A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Advanced Digestive System Tumor

China
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China
Ascentage Pharma Group Inc.

Recruiting

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: IMS001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations